Sangamo Therapeutics Stock Probability Of Bankruptcy

SGMO Stock

USD 1.96 0.01 0.51%

Sangamo Therapeutics' chance of distress is over 50% at this time. It has a moderate odds of going through some financial hardship in the next 2 years. Odds of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Sangamo balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Sangamo Therapeutics Piotroski F Score and Sangamo Therapeutics Altman Z Score analysis.

To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

As of the 22nd of November 2024, Market Cap is likely to drop to about 81 M. In addition to that, Enterprise Value is likely to drop to about 75 M

Sangamo Therapeutics Company odds of distress Analysis

Sangamo Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Sangamo Therapeutics Probability Of Bankruptcy

Over 55%

Most of Sangamo Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangamo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Sangamo Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Sangamo Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Sangamo Therapeutics financial health.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.24)

Revenue Per Share

0.066

Quarterly Revenue Growth

(0.95)

Return On Assets

(0.58)

Return On Equity

(1.94)

The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

	Total Assets	Total Stockholder Equity	Retained Earnings	Total Liab	Accounts Payable	Net Receivables	Short Term Investments	Total Current Assets	Common Stock	Net Debt	Property Plant Equipment	Current Deferred Revenue	Good Will	Short Term Debt	Intangible Assets	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	-0.4	0.97	0.42	0.41	0.89	0.97	0.03	-0.78	0.51	0.81	0.89	0.35	0.67	0.89	0.67	0.07	0.32	0.72	0.9	0.74	0.37
Total Stockholder Equity	0.97		-0.31	0.89	0.32	0.54	0.91	0.97	-0.1	-0.74	0.42	0.7	0.85	0.39	0.59	0.89	0.58	0.1	0.24	0.65	0.9	0.76	0.23
Retained Earnings	-0.4	-0.31		-0.48	-0.87	0.0	-0.11	-0.32	-0.22	0.19	-0.86	-0.78	-0.25	-0.48	-0.79	-0.56	-0.87	-0.09	0.16	-0.73	-0.01	0.26	-0.94
Total Liab	0.97	0.89	-0.48		0.51	0.26	0.82	0.92	0.16	-0.78	0.57	0.87	0.89	0.29	0.72	0.83	0.73	0.03	0.39	0.76	0.84	0.68	0.49
Accounts Payable	0.42	0.32	-0.87	0.51		-0.02	0.15	0.31	0.28	-0.15	0.69	0.68	0.34	0.42	0.72	0.46	0.78	-0.13	0.05	0.55	0.1	-0.16	0.93
Net Receivables	0.41	0.54	0.0	0.26	-0.02		0.41	0.39	-0.13	-0.06	-0.04	0.09	0.43	0.16	0.23	0.48	0.18	0.03	0.07	0.26	0.53	0.39	-0.09
Short Term Investments	0.89	0.91	-0.11	0.82	0.15	0.41		0.95	-0.14	-0.62	0.23	0.59	0.72	0.31	0.39	0.81	0.41	0.17	0.21	0.52	0.88	0.88	0.07
Total Current Assets	0.97	0.97	-0.32	0.92	0.31	0.39	0.95		-0.05	-0.75	0.44	0.76	0.82	0.33	0.59	0.9	0.57	0.13	0.21	0.66	0.88	0.79	0.25
Common Stock	0.03	-0.1	-0.22	0.16	0.28	-0.13	-0.14	-0.05		0.01	0.31	0.29	0.29	-0.26	0.47	0.09	0.29	-0.28	0.09	0.24	0.0	-0.1	0.41
Net Debt	-0.78	-0.74	0.19	-0.78	-0.15	-0.06	-0.62	-0.75	0.01		-0.4	-0.61	-0.77	-0.11	-0.46	-0.58	-0.44	0.1	-0.33	-0.49	-0.73	-0.61	-0.15
Property Plant Equipment	0.51	0.42	-0.86	0.57	0.69	-0.04	0.23	0.44	0.31	-0.4		0.8	0.46	0.32	0.88	0.6	0.8	0.12	-0.24	0.84	0.18	-0.08	0.75
Current Deferred Revenue	0.81	0.7	-0.78	0.87	0.68	0.09	0.59	0.76	0.29	-0.61	0.8		0.65	0.37	0.88	0.84	0.86	0.09	0.2	0.83	0.52	0.32	0.76
Good Will	0.89	0.85	-0.25	0.89	0.34	0.43	0.72	0.82	0.29	-0.77	0.46	0.65		0.09	0.68	0.71	0.58	-0.18	0.37	0.64	0.91	0.71	0.29
Short Term Debt	0.35	0.39	-0.48	0.29	0.42	0.16	0.31	0.33	-0.26	-0.11	0.32	0.37	0.09		0.25	0.5	0.49	0.36	0.02	0.33	0.07	-0.04	0.37
Intangible Assets	0.67	0.59	-0.79	0.72	0.72	0.23	0.39	0.59	0.47	-0.46	0.88	0.88	0.68	0.25		0.76	0.85	-0.15	0.02	0.81	0.44	0.17	0.77
Net Tangible Assets	0.89	0.89	-0.56	0.83	0.46	0.48	0.81	0.9	0.09	-0.58	0.6	0.84	0.71	0.5	0.76		0.74	0.14	0.07	0.77	0.7	0.55	0.47
Capital Surpluse	0.67	0.58	-0.87	0.73	0.78	0.18	0.41	0.57	0.29	-0.44	0.8	0.86	0.58	0.49	0.85	0.74		0.03	0.03	0.88	0.38	0.1	0.87
Deferred Long Term Liab	0.07	0.1	-0.09	0.03	-0.13	0.03	0.17	0.13	-0.28	0.1	0.12	0.09	-0.18	0.36	-0.15	0.14	0.03		-0.21	0.31	-0.11	-0.07	-0.07
Long Term Investments	0.32	0.24	0.16	0.39	0.05	0.07	0.21	0.21	0.09	-0.33	-0.24	0.2	0.37	0.02	0.02	0.07	0.03	-0.21		-0.07	0.43	0.39	0.04
Long Term Debt Total	0.72	0.65	-0.73	0.76	0.55	0.26	0.52	0.66	0.24	-0.49	0.84	0.83	0.64	0.33	0.81	0.77	0.88	0.31	-0.07		0.47	0.23	0.65
Net Invested Capital	0.9	0.9	-0.01	0.84	0.1	0.53	0.88	0.88	0.0	-0.73	0.18	0.52	0.91	0.07	0.44	0.7	0.38	-0.11	0.43	0.47		0.92	0.02
Net Working Capital	0.74	0.76	0.26	0.68	-0.16	0.39	0.88	0.79	-0.1	-0.61	-0.08	0.32	0.71	-0.04	0.17	0.55	0.1	-0.07	0.39	0.23	0.92		-0.23
Capital Stock	0.37	0.23	-0.94	0.49	0.93	-0.09	0.07	0.25	0.41	-0.15	0.75	0.76	0.29	0.37	0.77	0.47	0.87	-0.07	0.04	0.65	0.02	-0.23

	2019	2020	2021	2022	2023	2024 (projected)
Gross Profit Margin	(0.8)	(0.36)	(0.42)	0.91	0.89	(0.26)
Net Debt	(36.0M)	(89.2M)	(130.8M)	(57.3M)	(7.1M)	(7.5M)
Total Current Liabilities	69.9M	143.5M	127.9M	111.7M	47.7M	34.0M
Non Current Liabilities Total	134.9M	297.6M	218.7M	155.8M	34.7M	57.7M
Total Assets	637.5M	938.6M	721.9M	562.5M	165.3M	218.1M
Total Current Assets	405.5M	659.7M	398.8M	300.3M	94.3M	175.7M
Total Cash From Operating Activities	(144.4M)	169.9M	(233.3M)	(223.6M)	(224.8M)	(213.6M)

	Return On Equity	-1.94
	Return On Asset	-0.58
	Operating Margin	(94.13) %
	Current Valuation	397.47 M
	Shares Outstanding	208.22 M
	Shares Owned By Insiders	2.38 %
	Shares Owned By Institutions	38.53 %
	Number Of Shares Shorted	18.98 M
	Price To Earning	(15.31) X
	Price To Book	10.45 X
	Price To Sales	7.78 X
	Revenue	176.23 M
	Gross Profit	(138.6 M)
	EBITDA	(87.43 M)
	Net Income	(257.83 M)
	Cash And Equivalents	315.72 M
	Cash Per Share	2.02 X
	Total Debt	38.1 M
	Debt To Equity	0.13 %
	Current Ratio	2.86 X
	Book Value Per Share	0.47 X
	Cash Flow From Operations	(224.84 M)
	Short Ratio	1.92 X
	Earnings Per Share	(1.24) X
	Target Price	4.8
	Number Of Employees	405
	Beta	1.1
	Market Capitalization	563.24 M
	Total Asset	165.32 M
	Retained Earnings	(1.41 B)
	Working Capital	46.6 M
	Current Asset	212.58 M
	Current Liabilities	20.1 M
	Net Asset	165.32 M

0.85	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.83	PALI	Palisade Bio	Pair Corr
0.8	INZY	Inozyme Pharma	Pair Corr
0.74	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.74	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr

Sangamo Therapeutics Stock Probability Of Bankruptcy

Sangamo Therapeutics Company odds of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Sangamo Therapeutics Probability Of Bankruptcy

Sangamo Probability Of Bankruptcy Driver Correlations

Sangamo Probability Of Bankruptcy Peer Comparison

Sangamo Therapeutics Main Bankruptcy Drivers

Sangamo Fundamentals

About Sangamo Therapeutics Fundamental Analysis

Pair Trading with Sangamo Therapeutics

Moving together with Sangamo Stock

Moving against Sangamo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY